MRCP
TEVA icon

Maple Rock Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Maple Rock Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,208,741
Closed -$92.8M – 46
2024
Q4 		$92.8M Sell
4,208,741
-350,660
-8% -$6.38M 2.78% 5
2024
Q3 		$82.2M Buy
4,559,401
+47,000
+1% +$823K 2.33% 10
2024
Q2 		$73.3M Buy
4,512,401
+149,000
+3% +$2.29M 2.49% 9
2024
Q1 		$61.6M Buy
4,363,401
+1,770,000
+68% +$22.3M 3.41% 10
2023
Q4 		$27.1M Buy
+2,593,401
New +$24.2M 1.54% 24

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Maple Rock Capital Partners's TEVA Position: Q1 2025 in Review

Maple Rock Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 4,208,741 shares — an estimated $92.8M sold.

Maple Rock Capital Partners first reported a position in TEVA in Q4 2023 and held it in 5 quarters. The position peaked at $92.8M in Q4 2024. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Maple Rock Capital Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Maple Rock Capital Partners sold 4,208,741 Teva Pharmaceuticals shares in Q1 2025, an estimated $92.8M.
  • Maple Rock Capital Partners first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Maple Rock Capital Partners's Teva Pharmaceuticals position peaked at $92.8M in Q4 2024.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Maple Rock Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.